Pharmaceuticals.jpg

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

144060-53-7

Febuxostat

144060-53-7
1448346-29-9

Fenbendazole-amine HCl

1448346-29-9
162320-67-4

Flufenzine

162320-67-4
5104-49-4

Flurbiprofen

5104-49-4
83799-24-0

Fexofenadine

83799-24-0
11015-37-5

Flavomycin

11015-37-5
1847-24-1

Flucloxacillin sodium

1847-24-1
86393-33-1

Fluoroquinolonic acid

86393-33-1
67-73-2

Fluocinolone acetonide

67-73-2
26016-99-9

Fosfomycin 2Na

26016-99-9
25812-30-0

Gemfibrozil

25812-30-0
1222-05-5

Galaxolide

1222-05-5
1405-41-0

Gentamycine sulfate

1405-41-0
145435-72-9

Gamithromycin

145435-72-9
60142-96-3

Gabapentin

60142-96-3
122111-03-9

Gemcitabine HCl

122111-03-9
82410-32-0

Ganciclovir

82410-32-0
126-07-8

Griseofulvin

126-07-8
64744-50-9

Gabapentin Related compound A/ 4,4-Pentamethylene-2-pyrrolidone

64744-50-9
60142-96-3

Gabapentin USP

60142-96-3